89bio, Inc. (ETNB) Financial Statements (2026 and earlier)

Company Profile

Business Address 655 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:638,800,000440,000,000423,800,000531,400,000562,300,000578,900,000
Cash and cash equivalent315,396,000126,060,00091,411,000212,218,000217,573,000316,161,000
Short-term investments323,384,000313,895,000332,363,000319,166,000344,715,000262,709,000
Other undisclosed cash, cash equivalents, and short-term investments20,00045,00026,00016,00012,00030,000
Prepaid expense3,230,0003,945,0003,183,0002,916,0003,485,0003,085,000
Other undisclosed current assets40,914,00032,505,00029,223,00045,538,0008,997,00011,549,000
Total current assets:682,944,000476,450,000456,206,000579,854,000574,782,000593,534,000
Noncurrent Assets
Operating lease, right-of-use asset1,409,0001,572,0001,760,0001,942,0002,118,0002,293,000
Property, plant and equipment85,00023,00017,00027,00037,00046,000
Other noncurrent assets593,000640,000314,000315,000385,000396,000
Total noncurrent assets:2,087,0002,235,0002,091,0002,284,0002,540,0002,735,000
TOTAL ASSETS:685,031,000478,685,000458,297,000582,138,000577,322,000596,269,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37,133,00035,402,00038,388,00036,124,00035,647,00029,115,000
Accounts payable14,790,00015,382,00019,490,00017,461,00015,352,0008,585,000
Accrued liabilities22,343,00020,020,00018,898,00018,663,00020,295,00020,530,000
Debt    4,770,0001,892,000 
Other undisclosed current liabilities751,000727,000743,000759,000702,000496,000
Total current liabilities:37,884,00036,129,00039,131,00041,653,00038,241,00029,611,000
Noncurrent Liabilities
Long-term debt and lease obligation35,940,00035,732,00035,544,00020,355,00023,065,00024,795,000
Long-term debt, excluding current maturities35,940,00035,732,00035,544,00020,355,00023,065,00024,795,000
Liabilities, other than long-term debt5,749,0006,035,0005,520,0005,213,0005,477,0005,557,000
Other liabilities4,566,0004,429,0003,752,0003,750,0003,837,0003,740,000
Operating lease, liability888,0001,090,0001,281,0001,463,0001,640,0001,817,000
Derivative instruments and hedges, liabilities 295,000516,000487,000   
Total noncurrent liabilities:41,689,00041,767,00041,064,00025,568,00028,542,00030,352,000
Total liabilities:79,573,00077,896,00080,195,00067,221,00066,783,00059,963,000
Equity
Equity, attributable to parent605,458,000400,789,000378,102,000514,917,000510,539,000536,306,000
Common stock146,000120,000106,000105,00095,00093,000
Additional paid in capital1,500,713,0001,224,617,0001,082,884,0001,072,579,0001,020,076,000993,455,000
Accumulated other comprehensive income (loss)385,000563,0001,269,000(683,000)(519,000)190,000
Accumulated deficit(895,786,000)(824,511,000)(706,157,000)(557,084,000)(509,113,000)(457,432,000)
Total equity:605,458,000400,789,000378,102,000514,917,000510,539,000536,306,000
TOTAL LIABILITIES AND EQUITY:685,031,000478,685,000458,297,000582,138,000577,322,000596,269,000

Income Statement (P&L) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Operating expenses(75,909,000)(122,005,000)(151,938,000)(53,436,000)(57,277,000)(41,206,000)
Operating loss:(75,909,000)(122,005,000)(151,938,000)(53,436,000)(57,277,000)(41,206,000)
Nonoperating income
(Other Nonoperating income)
6,038,0005,099,0005,431,0006,473,0006,556,0005,704,000
Interest and debt expense    (874,000)(863,000)(866,000)
Loss from continuing operations before equity method investments, income taxes:(69,871,000)(116,906,000)(146,507,000)(47,837,000)(51,584,000)(36,368,000)
Other undisclosed loss from continuing operations before income taxes(1,267,000)(1,191,000)(2,362,000)   
Loss from continuing operations before income taxes:(71,138,000)(118,097,000)(148,869,000)(47,837,000)(51,584,000)(36,368,000)
Income tax expense(137,000)(257,000)(204,000)(134,000)(97,000) 
Other undisclosed loss from continuing operations      (3,867,000)
Net loss available to common stockholders, diluted:(71,275,000)(118,354,000)(149,073,000)(47,971,000)(51,681,000)(40,235,000)

Comprehensive Income (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net loss:(71,275,000)(118,354,000)(149,073,000)(47,971,000)(51,681,000)(40,235,000)
Other comprehensive income (loss)(178,000)(706,000)1,952,000(164,000)(709,000)737,000
Comprehensive loss, net of tax, attributable to parent:(71,453,000)(119,060,000)(147,121,000)(48,135,000)(52,390,000)(39,498,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: